Corbus Pharmaceuticals Holdings (CRBP) Change in Account Payables (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Change in Account Payables of -$1.3 million for Q3 2025, down 165.37% year-over-year from $2.0 million in Q3 2024, and down 829.14% quarter-over-quarter from $175000.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Change in Account Payables (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Change in Account Payables history runs 13 years deep, the most recent figure standing at -$1.3 million for Q3 2025.
- In Q3 2025, Change in Account Payables fell 165.37% year-over-year to -$1.3 million; the TTM figure through Sep 2025 stood at -$107000.0 (up 93.2% YoY), while the FY2024 annual figure was $1.6 million, up 55.93% from the prior year.
- Change in Account Payables for Q3 2025 stood at -$1.3 million, down from $175000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.2 million in Q3 2023, with the low at -$3.7 million in Q1 2021.
- The 5-year median for Change in Account Payables is -$759706.0 (2021), against an average of -$282480.6.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 493.74% in 2023, then plunged 586.81% in 2024.
- Corbus Pharmaceuticals Holdings' Change in Account Payables stood at -$759706.0 in 2021, then jumped by 229.06% to $980459.0 in 2022, then plunged by 252.89% to -$1.5 million in 2023, then surged by 211.94% to $1.7 million in 2024, then slumped by 176.04% to -$1.3 million in 2025.
- Business Quant data shows CRBP's Change in Account Payables at -$1.3 million in Q3 2025, $175000.0 in Q2 2025, and -$684000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.28 Mn |
| Sep 30, 2025 | -1.28 Mn |
| Jun 30, 2025 | 175,000.00 |
| Jun 30, 2025 | 175,000.00 |
| Mar 31, 2025 | -684,000.00 |
| Mar 31, 2025 | -684,000.00 |
| Dec 31, 2024 | 1.68 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | -896,000.00 |
| Jun 30, 2024 | -896,000.00 |
| Mar 31, 2024 | -1.13 Mn |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | -1.50 Mn |
| Dec 31, 2023 | -1.50 Mn |
| Sep 30, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.19 Mn |
| Jun 30, 2023 | 184,056.00 |
| Jun 30, 2023 | 184,056.00 |